Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | Imfinzi (durvalumab) - (VOLGA) | Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (MIBC) | Phase 3 | Ongoing | Intravenous | Oncology |
| AstraZeneca PLC | ULTOMIRIS (ravulizumab-cwvz) - (ICAN) | Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) | Phase 3 | Ongoing | Intravenous | Hematology |
| AstraZeneca PLC | IMFINZI (Durvalumab) + TACE - (EMERALD-3) | Locoregional Hepatocellular carcinoma (HCC) | Phase 3 | Data Released | Intravenous | Oncology |
| AstraZeneca PLC | ORPATHYS (savolitinib) + TAGRISSO (osimertinib) - (SAFFRON) | Non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | oral | Oncology |
| AstraZeneca PLC | IMFINZI (durvalumab) - (CALLA) | Cervical cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| AstraZeneca PLC | Imfinzi (durvalumab) - (ADJUVANT BR.31) | Early-stage (IB-IIIA) non-small cell lung cancer (NSCLC) | Phase 3 | Trial Discontinued | Intravenous | Oncology |
| AstraZeneca PLC | ION449 (AZD8233) - (SOLANO) | Hypercholesterolemia | Phase 2b | Trial Discontinued | Subcutaneous | Cardiology |
| AstraZeneca PLC | FASENRA (benralizumab) - (NATRON) | Hyper-eosinophilic syndrome (HES) | Phase 3 | Data Released | Subcutaneous | Immunology |
